The Sound of Evolution
Aripiprazole
Mechanism of action:
Aripiprazole has a unique multimodal neurotransmitter-regulating mechanism. It acts as a partial agonist at dopamine D₂ receptors. When dopamine levels are too low, it can moderately stimulate D₂ receptors and help regulate dopamine signaling related to mood and motivation. When dopamine levels are too high, it competitively suppresses D₂ receptor activity and reduces excessive dopamine signaling. As a result, it helps stabilize the dopamine system rather than simply blocking it. It also acts as a partial agonist at 5-HT₁A receptors, enhancing serotonergic activity, and as an antagonist at 5-HT₂A receptors, thereby modulating serotonin-dopamine interactions within specific cortical-limbic circuits.
Reference(s):
1. Nasrallah HA et al. (2008). Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry.
2. Bauman JN et al. (2008). Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug. Drug Metab Dispos.
3. Kubo M et al. (2007). Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. Drug Metab Pharmacokinet.